| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2014PLoSO...9k1079C |
| P356 | DOI | 10.1371/JOURNAL.PONE.0111079 |
| P932 | PMC publication ID | 4217760 |
| P698 | PubMed publication ID | 25365558 |
| P5875 | ResearchGate publication ID | 267753492 |
| P2093 | author name string | Gang Han | |
| Limin Cao | |||
| Ben Gu | |||
| HaiFang Yin | |||
| P2860 | cites work | Targeted disruption of exon 52 in the mouse dystrophin gene induced muscle degeneration similar to that observed in Duchenne muscular dystrophy. | Q52527217 |
| An error in dystrophin mRNA processing in golden retriever muscular dystrophy, an animal homologue of Duchenne muscular dystrophy | Q59416437 | ||
| Local dystrophin restoration with antisense oligonucleotide PRO051 | Q80412961 | ||
| Diaphragm rescue alone prevents heart dysfunction in dystrophic mice | Q82381994 | ||
| Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study | Q24616493 | ||
| Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study | Q24643018 | ||
| Inhibition of human esophageal squamous cell carcinomas by targeted silencing of tumor enhancer genes: an overview | Q26822792 | ||
| Old and new therapeutic developments in steroid treatment in Duchenne muscular dystrophy | Q26852709 | ||
| Dystrophin and utrophin influence fiber type composition and post-synaptic membrane structure. | Q30326812 | ||
| Morpholinos and their peptide conjugates: therapeutic promise and challenge for Duchenne muscular dystrophy | Q34021322 | ||
| Animal models for muscular dystrophy: valuable tools for the development of therapies | Q34045919 | ||
| Systemic administration of PRO051 in Duchenne's muscular dystrophy | Q34172661 | ||
| In-frame Dystrophin Following Exon 51-Skipping Improves Muscle Pathology and Function in the Exon 52–Deficient mdx Mouse | Q34343780 | ||
| Chronic systemic therapy with low-dose morpholino oligomers ameliorates the pathology and normalizes locomotor behavior in mdx mice | Q34556906 | ||
| Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse | Q34582428 | ||
| Effective exon skipping and dystrophin restoration by 2'-o-methoxyethyl antisense oligonucleotide in dystrophin-deficient mice | Q34711962 | ||
| Therapeutic approaches to muscular dystrophy. | Q34982869 | ||
| Pip5 transduction peptides direct high efficiency oligonucleotide-mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice. | Q35084227 | ||
| Evolving therapeutic strategies for Duchenne muscular dystrophy: targeting downstream events | Q35942405 | ||
| Towards developing standard operating procedures for pre-clinical testing in the mdx mouse model of Duchenne muscular dystrophy | Q36841572 | ||
| Advances in circulating microRNAs as diagnostic and prognostic markers for ovarian cancer | Q37386222 | ||
| Challenges to oligonucleotides-based therapeutics for Duchenne muscular dystrophy. | Q37907407 | ||
| Pharmacokinetic properties of 2'-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats | Q38304110 | ||
| Antisense-induced myostatin exon skipping leads to muscle hypertrophy in mice following octa-guanidine morpholino oligomer treatment. | Q38340328 | ||
| Dantrolene enhances antisense-mediated exon skipping in human and mouse models of Duchenne muscular dystrophy | Q39225878 | ||
| Preclinical PK and PD studies on 2'-O-methyl-phosphorothioate RNA antisense oligonucleotides in the mdx mouse model | Q39880997 | ||
| Optimization of peptide nucleic acid antisense oligonucleotides for local and systemic dystrophin splice correction in the mdx mouse. | Q39882118 | ||
| Mdx mice inducibly expressing dystrophin provide insights into the potential of gene therapy for duchenne muscular dystrophy | Q40743665 | ||
| Long-term rescue of dystrophin expression and improvement in muscle pathology and function in dystrophic mdx mice by peptide-conjugated morpholino | Q42257279 | ||
| Differential expression of dystrophin isoforms in strains of mdx mice with different mutations | Q42640377 | ||
| In vitro evaluation of novel antisense oligonucleotides is predictive of in vivo exon skipping activity for Duchenne muscular dystrophy. | Q42653096 | ||
| A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice. | Q43289513 | ||
| Effective exon skipping and restoration of dystrophin expression by peptide nucleic acid antisense oligonucleotides in mdx mice | Q44264343 | ||
| Use of the dog model for Duchenne muscular dystrophy in gene therapy trials. | Q44434265 | ||
| Dystrophin-deficient pigs provide new insights into the hierarchy of physiological derangements of dystrophic muscle | Q44717757 | ||
| In vivo comparison of 2'-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping | Q45002735 | ||
| Targeted exon skipping in transgenic hDMD mice: A model for direct preclinical screening of human-specific antisense oligonucleotides | Q45007187 | ||
| Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse | Q45863474 | ||
| Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology | Q46917397 | ||
| Subcellular fractionation of dystrophin to the triads of skeletal muscle | Q46932900 | ||
| Targeting RNA: an emerging hope for treating muscular dystrophy | Q47624821 | ||
| Solubilization and concentration of carbon dioxide: novel spray reactors with immobilized carbonic anhydrase | Q47983277 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | e111079 | |
| P577 | publication date | 2014-11-03 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Wild-type mouse models to screen antisense oligonucleotides for exon-skipping efficacy in Duchenne muscular dystrophy | |
| P478 | volume | 9 |
| Q64261365 | Correction: Correction: Wild-Type Mouse Models to Screen Antisense Oligonucleotides for Exon-Skipping Efficacy in Duchenne Muscular Dystrophy |
| Q59804053 | Correction: Wild-Type Mouse Models to Screen Antisense Oligonucleotides for Exon-Skipping Efficacy in Duchenne Muscular Dystrophy |
| Q36939725 | Peptide Nucleic Acid Promotes Systemic Dystrophin Expression and Functional Rescue in Dystrophin-deficient mdx Mice |
| Q92130410 | Splice modulating antisense oligonucleotides restore some acid-alpha-glucosidase activity in cells derived from patients with late-onset Pompe disease |
Search more.